Published: 25 November 2023
Author(s): Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, Henning Grønbæk, Karen Louise Thomsen
Issue: May 2024
Section: Invited Review Article

Non-alcoholic fatty liver disease (NAFLD) has for years been the most common liver disease worldwide. In 2016, the prevalence of NAFLD was estimated to be approximately 25 % [1], and recent reports suggest that the overall prevalence in 2023 has increased to 30 % with regional differences [2,3]. NAFLD can progress to non-alcoholic steatohepatitis (NASH) with development of fibrosis, and further progression to cirrhosis with its complications including an increased risk of primary liver cancer. Patients with advanced liver fibrosis have increased risk of liver-related morbidity and mortality, whereas cardiovascular disease (CVD) is the leading cause of death in any stage of NAFLD [4].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.